Madrigal Pharma (MDGL) Tops Q4 EPS by $1.77, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Madrigal Pharmaceuticals (MDGL) PT Raised to $405 at H.C. Wainwright
February 27, 2025 6:05 AM ESTH.C. Wainwright analyst Ed Acre raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $405.00 (from $400.00) while maintaining a Buy rating.
The analyst comments "We upgrade STLD to Peer Perform from Underperform, using updated steel price forecasts on Trump's pledged 25%... More
TD Cowen Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL), PT $390
February 26, 2025 3:55 PM ESTTD Cowen analyst Ritu Baral reiterated a Buy rating and $390.00 price target on Madrigal Pharmaceuticals (NASDAQ: MDGL)
The analyst comments "4Q/FY24 Rezdiffra revs were $103M/$180M, at the top of the preannouncement range. As of YE24, 11.8K+ pts were on Tx.... More
Madrigal Pharmaceuticals (MDGL) PT Raised to $469 at Citi
February 26, 2025 3:52 PM ESTCiti analyst David Lebowitz raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $469.00 (from $378.00) while maintaining a Buy rating.
The analyst comments "Madrigal reported 4Q24 financial results, exceeding sales expectations for Rezdiffra for the third consecutive quarter since its launch... More
